Terms ending in 2043
Every in-force patent on Biogen MA Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,551,669 | Medical System Including Two Access Ports In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,565,504 | Spirocyclic O-GLYCOPROTEIN-2-Acetamido-2-Deoxy-3-D-GLUCOPYRANOSIDASE Inhibitors In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,565,500 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AND PYRROLO[2,1-f][1,2,4]TRIAZINES AS BTK INHIBITORS In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,709,621 | TYK2 Inhibitors In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,656,353 | Biomarkers of Progressive Multifocal Leukoencephalopathy In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,747,241 | Compounds for Targeting Degradation of Bruton's Tyrosine Kinase In force · High confidence | C4 Therapeutics, Inc. | In force | High confidence | |
| US 12,570,631 | Substituted N-(4-(PYRIMIDIN and PYRIDIN-4-YL)BENZYLCARBOXAMIDES and Its Use for Treating Disorders Responsive to Inhibition of BTK In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,799,197 | Anti-Transferrin Receptor Antibodies and Uses Thereof In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,692,495 | Methods of Preparing Oligonucleotide Compositions Using Ultrafiltration/Diafiltration In force · High confidence | Biogen MA Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
8 of these are in force and held by Biogen MA Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.